Wedbush Maintains Outperform On Omeros Following Phase 2 Dosing Completion
In a research report issued today, Wedbush analyst Liana Moussatos maintained an Outperform rating on Omeros (NASDAQ:OMER) with a price target of $52, following the company’s announcement of initial results from the low-dose cohort of its Phase 2 proof-of-concept study testing OMS721 for the treatment of atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathies (TMAs).
Moussatos wrote, “Although there is no mention of statistical significance and no quantification of data, all three patients treated with low dose OMS721 responded with improved platelet counts compared to baseline. Additional disease markers, including serum LDH, haptoglobin and creatinine levels showed patient dependent improvement. A European physician requested extended access to OMS721 for compassionate use in two patients—which suggests to us that the physician believes OMS721 is having a clinical benefit. Of note, the third patient, who responded to OMS721 treatment, was removed from the trial due to a serious localized inflammatory response – which is likely the result of a pre-existing condition. This patient subsequently relapsed following termination of OMS721 treatment. No additional safety issues were observed.”
According to TipRanks.com, which tracks and ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, analyst Liana Moussatos has a total average return of 59.9% and a 78.8% success rate. Moussatos has a 59.3% average return when recommending OMER, and is ranked #2 out of 3479 analysts.